- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Thomas Graf Discusses the Effect of Novel Therapies on Private Coverage
Thomas Graf, MD, chief medical officer and vice president, Horizon Blue Cross Blue Shield of New Jersey, discusses the impact of new therapies on private insurance coverage for cancer patients.
Thomas Graf, MD, chief medical officer and vice president, Horizon Blue Cross Blue Shield of New Jersey, discusses the impact of new therapies on private insurance coverage for cancer patients.
Transcript
Will novel therapies have an effect on private coverage?
It’s going to drive cost in a way that’s not been seen. I mean, we’ve seen some explosion in pharmacy costs now exceeding often the physician costs for health insurers. That’s gonna leap another factor here, is that the drug costs continue to escalate as new therapies continue to be produced for more and more patients. The potential number of patients that are eligible for some of the drugs that are available is quite small. The newer drugs will have much wider approachable patient panels. So, the ability to impact total cost for insurers, for employers, for the federal government is dramatic. So, I think some employers will thereby not be able to offer coverage because it will become so expensive to their employees which will drive them to different markets. Clearly, there’s a reduction in the insurance mandate. So, I suspect a lot of patients will go from having private coverage to not having private coverage and then we’re going to have a real issue because access to those drugs will be very restricted in that group.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
STEER Data Open Door to SMA Gene Therapy for Wider Age Range of Children
March 19th 2025Delivery of onasemnogene abeparvovec into the intrathecal space was safe and effective for children with spinal muscular atrophy (SMA) aged 2 to 17 years, who had previously been shut out of receiving gene therapy.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
